Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548701 · ClinicalTrials.gov registry record
Thromboelastometry Prediction Utility for Risk of Abortion
A clinical trial of Pregnancy Trimester, First and Abortion, Threatened, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 98
- Enrollment target
- 1
- Study location
NCT03548701: Completed study of Pregnancy Trimester, First and Abortion, Threatened, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03548701 is a study of Pregnancy Trimester, First and Abortion, Threatened that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 98 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03548701, a study of Pregnancy Trimester, First and Abortion, Threatened, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use thromboelastometry in ED patients with vaginal bleeding, as well as healthy pregnant controls, to determine if abnormal results are associated with the presence of vaginal bleeding as well as later complications during pregnancy.
Primary Outcome
Thromboelastometry measurement of the Maximum Clot Firmness over the duration of the test. Performed as part of InTEM (response to ellagic acid) and ExTEM (response to tissue factor) measures.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Thromboelastometry testing
Study Locations (1)
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2019-05-15 |
What the finished NCT03548701 record still lists
NCT03548701 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 2 conditions, with Pregnancy Trimester, First appearing as the primary indexed condition, and to 1 intervention - of which Thromboelastometry testing is the first listed.
NCT03548701 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03548701 about?
NCT03548701 is a clinical study titled "Thromboelastometry Prediction Utility for Risk of Abortion". This study will use thromboelastometry in ED patients with vaginal bleeding, as well as healthy pregnant controls, to determine if abnormal results are associated with the presence of vaginal bleeding as well as later complications during pregnancy.
What is the current status of trial NCT03548701?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2018-06-04. Estimated completion is 2019-05-15.
What conditions does trial NCT03548701 study?
This clinical trial studies the following conditions: Pregnancy Trimester, First, Abortion, Threatened.
What interventions are being tested in trial NCT03548701?
The interventions under investigation include: Thromboelastometry testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03548701?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03548701 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI